---
document_datetime: 2025-12-29 11:58:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/glybera.html
document_name: glybera.html
version: success
processing_time: 0.1268315
conversion_datetime: 2025-12-30 01:54:58.5256
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Glybera

[RSS](/en/individual-human-medicine.xml/66034)

##### Expired

This medicine's authorisation has expired

alipogene tiparvovec Medicine Human Expired

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Glybera](#more-information-on-glybera-592)
- [More information on Glybera](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Glybera (alipogene tiparvovec) expired on 28 October 2017 following the decision of the marketing authorisation holder, uniQure biopharma B.V., not to apply for a renewal of the marketing authorisation.

uniQure biopharma B.V. confirmed that it did not apply for renewal of the authorisation due to the lack of demand for this product. Glybera was granted marketing authorisation in the European Union (EU) on 25 October 2012 as a one time, single-administration gene therapy for adult patients with familial lipoprotein lipase deficiency. The marketing authorisation was valid for a 5-year period.

The European Public Assessment Report (EPAR) for Glybera is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

This product was originally designated an orphan medicine on 8 March 2004. Glybera was withdrawn from the Community register of orphan medicinal products by the European Commission in October 2017 at the time of the withdrawal of the marketing authorisation.

Glybera : EPAR - Summary for the public

Reference Number: EMA/670094/2015

English (EN) (558.96 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 15/06/2016

[View](/en/documents/overview/glybera-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-520)

български (BG) (656.05 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/bg/documents/overview/glybera-epar-summary-public_bg.pdf)

español (ES) (554.14 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/es/documents/overview/glybera-epar-summary-public_es.pdf)

čeština (CS) (635.42 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/cs/documents/overview/glybera-epar-summary-public_cs.pdf)

dansk (DA) (552.4 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/da/documents/overview/glybera-epar-summary-public_da.pdf)

Deutsch (DE) (560.11 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/de/documents/overview/glybera-epar-summary-public_de.pdf)

eesti keel (ET) (546.33 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/et/documents/overview/glybera-epar-summary-public_et.pdf)

ελληνικά (EL) (665.76 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/el/documents/overview/glybera-epar-summary-public_el.pdf)

français (FR) (556.43 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/fr/documents/overview/glybera-epar-summary-public_fr.pdf)

hrvatski (HR) (578.62 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/hr/documents/overview/glybera-epar-summary-public_hr.pdf)

italiano (IT) (554.17 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/it/documents/overview/glybera-epar-summary-public_it.pdf)

latviešu valoda (LV) (613.09 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/lv/documents/overview/glybera-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (581.18 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/lt/documents/overview/glybera-epar-summary-public_lt.pdf)

magyar (HU) (627.73 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/hu/documents/overview/glybera-epar-summary-public_hu.pdf)

Malti (MT) (637.57 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/mt/documents/overview/glybera-epar-summary-public_mt.pdf)

Nederlands (NL) (557.63 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/nl/documents/overview/glybera-epar-summary-public_nl.pdf)

polski (PL) (635.92 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/pl/documents/overview/glybera-epar-summary-public_pl.pdf)

português (PT) (553.99 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/pt/documents/overview/glybera-epar-summary-public_pt.pdf)

română (RO) (577.91 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/ro/documents/overview/glybera-epar-summary-public_ro.pdf)

slovenčina (SK) (617.25 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/sk/documents/overview/glybera-epar-summary-public_sk.pdf)

slovenščina (SL) (626.63 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/sl/documents/overview/glybera-epar-summary-public_sl.pdf)

Suomi (FI) (547.63 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/fi/documents/overview/glybera-epar-summary-public_fi.pdf)

svenska (SV) (549.36 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

15/06/2016

[View](/sv/documents/overview/glybera-epar-summary-public_sv.pdf)

## Product information

Glybera : EPAR - Product Information

English (EN) (937.84 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 10/07/2017

[View](/en/documents/product-information/glybera-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-925)

български (BG) (1.75 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/bg/documents/product-information/glybera-epar-product-information_bg.pdf)

español (ES) (946.94 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/es/documents/product-information/glybera-epar-product-information_es.pdf)

čeština (CS) (1.46 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/cs/documents/product-information/glybera-epar-product-information_cs.pdf)

dansk (DA) (974.26 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/da/documents/product-information/glybera-epar-product-information_da.pdf)

Deutsch (DE) (985.62 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/de/documents/product-information/glybera-epar-product-information_de.pdf)

eesti keel (ET) (932.5 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/et/documents/product-information/glybera-epar-product-information_et.pdf)

ελληνικά (EL) (1.8 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/el/documents/product-information/glybera-epar-product-information_el.pdf)

français (FR) (960.7 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/fr/documents/product-information/glybera-epar-product-information_fr.pdf)

hrvatski (HR) (341.04 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/hr/documents/product-information/glybera-epar-product-information_hr.pdf)

íslenska (IS) (953.83 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/is/documents/product-information/glybera-epar-product-information_is.pdf)

italiano (IT) (950.73 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/it/documents/product-information/glybera-epar-product-information_it.pdf)

latviešu valoda (LV) (1.51 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/lv/documents/product-information/glybera-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.09 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/lt/documents/product-information/glybera-epar-product-information_lt.pdf)

magyar (HU) (1.45 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/hu/documents/product-information/glybera-epar-product-information_hu.pdf)

Malti (MT) (1.55 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/mt/documents/product-information/glybera-epar-product-information_mt.pdf)

Nederlands (NL) (991.9 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/nl/documents/product-information/glybera-epar-product-information_nl.pdf)

norsk (NO) (929.45 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/no/documents/product-information/glybera-epar-product-information_no.pdf)

polski (PL) (1.5 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/pl/documents/product-information/glybera-epar-product-information_pl.pdf)

português (PT) (973.92 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/pt/documents/product-information/glybera-epar-product-information_pt.pdf)

română (RO) (1.07 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/ro/documents/product-information/glybera-epar-product-information_ro.pdf)

slovenčina (SK) (1.49 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/sk/documents/product-information/glybera-epar-product-information_sk.pdf)

slovenščina (SL) (1.44 MB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/sl/documents/product-information/glybera-epar-product-information_sl.pdf)

Suomi (FI) (941.22 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/fi/documents/product-information/glybera-epar-product-information_fi.pdf)

svenska (SV) (971.14 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

10/07/2017

[View](/sv/documents/product-information/glybera-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** S/0057 20/04/2017

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Glybera : EPAR - All Authorised presentations

English (EN) (475.08 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 29/11/2012

[View](/en/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-704)

български (BG) (525.77 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/bg/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_bg.pdf)

español (ES) (472.78 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/es/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_es.pdf)

čeština (CS) (516.41 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/cs/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (472.29 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/da/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (475.24 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/de/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (475.1 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/et/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (525.73 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/el/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_el.pdf)

français (FR) (475.46 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/fr/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (474.76 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/is/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_is.pdf)

italiano (IT) (482.32 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/it/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (518.34 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/lv/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (505.74 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/lt/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (516.38 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/hu/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (524.09 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/mt/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (482.19 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/nl/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (482 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/no/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_no.pdf)

polski (PL) (525.74 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/pl/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_pl.pdf)

português (PT) (481.47 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/pt/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_pt.pdf)

română (RO) (504.17 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/ro/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (516.02 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/sk/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (514.33 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/sl/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (475.05 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/fi/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (475.66 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/sv/documents/all-authorised-presentations/glybera-epar-all-authorised-presentations_sv.pdf)

Glybera : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (473.72 KB - PDF)

**First published:** 29/11/2012

**Last updated:** 29/11/2012

[View](/en/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (23)](#file-language-dropdown-6)

български (BG) (531.29 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/bg/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (473.49 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/es/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (517.21 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/cs/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (466.34 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/da/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (474.21 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/de/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (465.59 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/et/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (532.62 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/el/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (473.88 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/fr/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (480.62 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/is/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (472.77 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/it/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (520.92 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/lv/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (494.22 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/lt/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (518.65 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/hu/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (520.3 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/mt/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (473.89 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/nl/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (473.61 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/no/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (555 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/pl/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (466.03 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/pt/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (494 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/ro/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (517.03 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/sk/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (514.83 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/sl/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (465.89 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/fi/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (466.42 KB - PDF)

**First published:**

29/11/2012

**Last updated:**

29/11/2012

[View](/sv/documents/conditions-member-states/glybera-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

## Product details

Name of medicine Glybera Active substance alipogene tiparvovec International non-proprietary name (INN) or common name alipogene tiparvovec Therapeutic area (MeSH) Hyperlipoproteinemia Type I Anatomical therapeutic chemical (ATC) code C10AX10

### Pharmacotherapeutic group

Lipid modifying agents

### Therapeutic indication

Glybera is indicated for adult patients diagnosed with familial lipoprotein lipase deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. The diagnosis of LPLD has to be confirmed by genetic testing. The indication is restricted to patients with detectable levels of LPL protein.

## Authorisation details

EMA product number EMEA/H/C/002145

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Marketing authorisation holder

uniQure biopharma B.V.

Meibergdreef 61 NL-1105 BA Amsterdam The Netherlands

Marketing authorisation issued 25/10/2012 Expiry of marketing authorisation 28/10/2017 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Glybera : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (772.1 KB - PDF)

**First published:** 03/09/2014

**Last updated:** 10/07/2017

[View](/en/documents/procedural-steps-after/glybera-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Glybera : EPAR - Public assessment report

Adopted

English (EN) (3.18 MB - PDF)

**First published:** 29/11/2012

**Last updated:** 29/11/2012

[View](/en/documents/assessment-report/glybera-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Glybera

Adopted

Reference Number: EMA/CHMP/472167/2012

English (EN) (511 KB - PDF)

**First published:** 20/07/2012

**Last updated:** 20/07/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-glybera_en.pdf)

Questions and answers on the refusal of the marketing authorisation for Glybera - Outcome of re-examination

Adopted

Reference Number: EMA/CHMP/474562/2011

English (EN) (506.11 KB - PDF)

**First published:** 21/10/2011

**Last updated:** 21/10/2011

[View](/en/documents/smop-initial/questions-and-answers-refusal-marketing-authorisation-glybera-outcome-re-examination_en.pdf)

Questions and answers on the recommendation for the refusal of the marketing authorisation for Glybera

Adopted

Reference Number: EMA/CHMP/474562/2011

English (EN) (63.72 KB - PDF)

**First published:** 24/06/2011

**Last updated:** 24/06/2011

[View](/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorisation-glybera_en.pdf)

#### More information on Glybera

- [Regulatory evaluation of Glybera in Europe - two committees, one mission](http://www.nature.com/nrd/journal/v12/n9/full/nrd3835-c1.html)

Questions and answers on the positive opinion on the marketing authorisation of Glybera (alipogene tiparvovec)

Reference Number: EMA/470328/2012

English (EN) (55.8 KB - PDF)

**First published:** 20/07/2012

**Last updated:** 20/07/2012

[View](/en/documents/medicine-qa/questions-answers-positive-opinion-marketing-authorisation-glybera-alipogene-tiparvovec_en.pdf)

#### More information on Glybera

- [EMEA-000292-PIP01-08-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000292-pip01-08-m03)
- [Glybera Registry, long-term safety and efficacy follow-up in Lipoprotein Lipase deficient (LPLD) patients treated with alipogene tiparvovec (GLYBERA®) - post-authorisation study](https://catalogues.ema.europa.eu/study/11889)

**This page was last updated on** 30/10/2017

## Share this page

[Back to top](#main-content)